iiinova — where your digital self keeps evolving

S. Evan Cooper 🦠 @scooper-id.bsky.social · 31/07/2026

Not to mention the dojo being located just one town over from a haunted breeding ground of ghost Pokémon…

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 05/07/2026

You heard it here first, folks. God is dead.

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 03/05/2026

You could tell who was chronically online by their frostbite

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 18/04/2026

Brooklyn Half Marathon training is so much nicer in bloom. 🌸🏃🏼

010

Reposted by S. Evan Cooper 🦠

Olga Nesterova @onestpress.onestnetwork.com · 23/01/2026

WHO removing Us Flag

62677353441

S. Evan Cooper 🦠 @scooper-id.bsky.social · 05/01/2026

The total health care spending for Medicare would increase from $11.4 billion in 2026 to $28.6 billion in 2035, which includes projected increases to the cost of ART, HIV-related care, and other costs not related to HIV.

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 05/01/2026

The increase in Medicare beneficiaries with HIV is projected to increase by 1.3-fold in those aged 65 to 69 years compared with 3.3-fold in those aged 80 years or older. Additionally, the total number of deaths would increase from 5500 in 2026 to 9640 in 2035.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 05/01/2026

The number of individuals using Medicare who have HIV, are using ART, and are aged 65 years or older is estimated to increase from 111,600 in 2026 to 193,560 in 2035, with increases in all age groups.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 05/01/2026

The number of Medicare beneficiaries living with HIV and receiving antiretroviral therapy (ART) will more than double in the next 10 years due to the life expectancy of people with HIV increasing.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 29/12/2025

That’s the most recorded in a single week since the department started tracking cases in 2004, the health department said in a statement.

010

S. Evan Cooper 🦠 @scooper-id.bsky.social · 29/12/2025

The New York State Department of Health said Friday that the state is experiencing a record high number of flu cases in a single week. State data show a total of 71,123 positive flu cases reported for the week ending December 20, an increase of 38% from the prior week.

110

S. Evan Cooper 🦠 @scooper-id.bsky.social · 24/12/2025

Within 12 weeks of enrollment, 93 participants (47.7%) completed follow-up and 69 (35.4%) were linked to care. Linkage to care did not differ significantly between groups. Time to linkage to care was significantly less for PWH in the intervention group in a modified intention-to-treat analysis.

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 24/12/2025

Study participants were randomly assigned to receive a laboratory-based plasma HIV VL test with next-day results in addition to the standard of care HIV antigen/antibody test result or to receive the standard of care HIV antigen/antibody assay alone.

110

S. Evan Cooper 🦠 @scooper-id.bsky.social · 23/12/2025

By week 48, 94.2% of the weekly group and 92.3% of the daily group had viral loads below 50 copies/mL. The proportion of patients with at least a 95% medication adherence rate was greater in the weekly group (98%) than in the daily group (86.3%).

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 23/12/2025

In 104 virologically suppressed adults with HIV-1 on the daily oral regimen of BIC/FTC/TAF, just 1 patient randomized to receive once-weekly islatravir-lenacapavir had a viral load of 50 copies/mL or greater after 24 weeks compared with none of those assigned to continue on the daily oral regimen.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 23/12/2025

A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic suppression compared with standard daily oral treatment in an open-label phase II trial.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 15/12/2025

On Thursday, the FDA also approved the expanded use of another new antibiotic, gepotidacin, to treat gonorrhea. The drug “had previously been approved to treat urinary tract infections in women.

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 15/12/2025

On Friday, the agency approved zoliflodacin, a new antibiotic, a day after an article published in The Lancet reported that a clinical trial had found that a single oral dose of the drug was safe and effective against gonorrhea.

110

S. Evan Cooper 🦠 @scooper-id.bsky.social · 15/12/2025

FDA Approves Two New Antibiotics To Treat Gonorrhea #IDSky #MedSky www.nytimes.com/2025/12/12/h...

nytimes.com

F.D.A. Approves Two New Drugs to Treat Gonorrhea

120

S. Evan Cooper 🦠 @scooper-id.bsky.social · 02/12/2025

The trial was an intensive experiment, requiring about 60 clinic visits over two years, and the cooperation of multiple research groups and pharmaceutical companies. It pooled together 3 immunotherapy approaches – drugs that ignite and shape a person’s immune response.

010

S. Evan Cooper 🦠 @scooper-id.bsky.social · 02/12/2025

In 6 participants, the virus rebounded slowly and stayed at a low level for months, and 1 person’s immune system kept the virus in check for more than a year and a half – giving hope that they could optimize the approach to create a cure.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 02/12/2025

A new small study shows a glimmer of hope in the long effort to control HIV without medication and search for a cure for a virus that attacks immune cells. Researchers gave 10 participants a complex regimen of experimental immunotherapies, then discontinued the daily pills that kept the virus at bay

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 02/12/2025

A senior Administration official stressed that the US would continue its work to combat HIV/AIDS, both through the new global health strategy and through the President’s Emergency Plan for AIDS Relief, or PEPFAR. Nevertheless, the efforts to unravel our country’s HIV response raise alarm bells.

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 02/12/2025

The federal government is not commemorating World AIDS Day this year as it has done for decades in the past. The commemoration has been marked every December 1 since 1988. The day is meant to raise awareness of efforts to fight the deadly infection and remember those died from it.

110

S. Evan Cooper 🦠 @scooper-id.bsky.social · 25/11/2025

So Nintendo be like: “I want that Star TOTALLY NAKED!”

010

S. Evan Cooper 🦠 @scooper-id.bsky.social · 22/11/2025

‘Alien’ RPG where you play as Jonesy the Cat and your objective is to lure as many crew members to their xenomorph deaths, please! #PAXUnolugged👾

010

S. Evan Cooper 🦠 @scooper-id.bsky.social · 21/11/2025

#BookSky - Did you enjoy reading Wuthering Heights? Thinking about giving it a read before the film adaptation in February. Embarking on a reread of Frankenstein and seem to be in the midst of my Classic Gothic Girlie author era.

030

S. Evan Cooper 🦠 @scooper-id.bsky.social · 21/11/2025

Rising drug resistance is a serious global public health threat. Meanwhile, zoliflodacin, an investigational antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ceftriaxone/azithromycin in phase 3 trials.

010

S. Evan Cooper 🦠 @scooper-id.bsky.social · 21/11/2025

The new WHO data found that between 2022 and 2024, resistance to ceftriaxone and cefixime rose from 0.8% to 5% and from 1.7% to 11%, respectively, with resistant strains detected in more countries. Resistance to azithromycin remained stable at 4%, while resistance to ciprofloxacin reached 95%.

120

S. Evan Cooper 🦠 @scooper-id.bsky.social · 21/11/2025

The WHO estimates that in 2020, there were 82.4 million new cases among adolescents and adults aged 15-49 years worldwide. The infection is treated with antibiotics, but one particular strain, Neisseria gonorrhoeae, is increasingly resistant to current anti-infective treatments.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 21/11/2025

I still think about Rita Ora every time I hear Zeraora…

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 20/11/2025

Gilead CEO Daniel O’Day said on a media call on Tuesday that the company was working with other governments in partnership with the Global Fund and PEPFAR and has submitted marketing authorizations through Rwanda, Tanzania, Botswana and several other countries.

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 20/11/2025

That’s the goal of the Global Fund, a major donor to combating HIV, tuberculosis and malaria, along with Gilead Sciences and the State Department.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 20/11/2025

The US State Department announced that Eswatini and Zambia have each received 500 doses of lenacapavir. The delivery marks the first small step toward providing at least 2 million doses to the highest burden countries, largely in Africa, by 2028.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 20/11/2025

In Eswatini, about 6,000 high-risk people are set to benefit from the drug’s initial rollout, primarily to prevent HIV transmission from mothers to newborns. The country currently has over 200,000 people living with HIV, with most receiving treatment funded by PEPFAR.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 20/11/2025

Lenacapavir was developed by Gilead Sciences and has demonstrated near-total protection in clinical studies. Its rollout, initially planned for 10 high-risk African countries, is part of the U.S. President’s Emergency Plan for AIDS Relief, or PEPFAR, in partnership with the Global Fund.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 20/11/2025

Eswatini and Zambia became the first African countries “o receive lenacapavir, the first twice-yearly HIV prevention injection hailed by global health officials as a game-changer in the fight against a virus that has killed tens of millions of people across the continent.

100

S. Evan Cooper 🦠 @scooper-id.bsky.social · 20/11/2025

The monthly oral pill was the most popular of the non-injectable options, with 61.6% preferring it. The daily oral pill saw 41.6% preferring it compared with 33.7% who preferred a removable implant and 35.7% who preferred event-driven oral PrEP.

000

S. Evan Cooper 🦠 @scooper-id.bsky.social · 20/11/2025

There were 44.5% of the participants who were actively taking PrEP, and 63.4% had taken PrEP at some point. They noted that injectable PrEP was favored by 53.4% of all the participants, with 25.1% preferring the injections every 2 months and 50.6% preferring an injection every 6 months.

100